Tyra Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
TYRA$22.30+5.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Balance Sheets
ce Sheets
(in thousands, except share and per share data)
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $91,966 | $58,006 |
| Marketable securities | 249,475 | 145,463 |
| Prepaid expenses and other current assets | 6,022 | 8,202 |
| Total current assets | 347,463 | 211,671 |
| Restricted cash | 1,000 | 1,000 |
| Property and equipment, net | 1,651 | 1,628 |
| Right-of-use assets | 6,068 | 6,526 |
| Other long-term assets | 7,376 | 5,032 |
| Total assets | $363,558 | $225,857 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $590 | $4,662 |
| Lease liabilities, current | 412 | 280 |
| Accrued expenses and other current liabilities | 13,592 | 10,391 |
| Total current liabilities | 14,594 | 15,333 |
| Lease liabilities, noncurrent | 5,810 | 6,216 |
| Other long-term liabilities | 3 | 46 |
| Total liabilities | 20,407 | 21,595 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 50,000,000 shares authorized at December 31, 2024 and December 31, 2023; no shares issued and outstanding at December 31, 2024 and December 31, 2023. | — | — |
| Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2024 and December 31, 2023; 50,754,262 and 43,099,055 shares issued at December 31, 2024 and December 31, 2023, respectively, and 50,749,945 and 43,024,634 shares outstanding at December 31, 2024 and December 31, 2023, respectively. | 5 | 4 |
| Additional paid-in capital | 593,687 | 368,707 |
| Accumulated other comprehensive income | 770 | 381 |
| Accumulated deficit | (251,311) | (164,830) |
| Total stockholders’ equity | 343,151 | 204,262 |
| Total liabilities and stockholders’ equity | $363,558 | $225,857 |
Statem
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.